JP2014530806A - 脂肪酸の２−ヒドロキシド誘導体のエナンチオマー - Google Patents

脂肪酸の２−ヒドロキシド誘導体のエナンチオマー Download PDF

Info

Publication number
JP2014530806A
JP2014530806A JP2014533953A JP2014533953A JP2014530806A JP 2014530806 A JP2014530806 A JP 2014530806A JP 2014533953 A JP2014533953 A JP 2014533953A JP 2014533953 A JP2014533953 A JP 2014533953A JP 2014530806 A JP2014530806 A JP 2014530806A
Authority
JP
Japan
Prior art keywords
level
cancer
enzyme
2ohoa
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014533953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530806A5 (enExample
Inventor
ルイス，パブロビセンテ エスクリバ
ルイス，パブロ ビセンテ エスクリバ
コブリン，グインドリン バルセロ
コブリン，グインドリン バルセロ
ローラ マルティン，マリア
ローラ マルティン，マリア
ヒメネス，シルビア テレス
ヒメネス，シルビア テレス
サルバ，マリア アントニア ノゲイラ
サルバ，マリア アントニア ノゲイラ
シャベット，ザビエル ブスケツ
シャベット，ザビエル ブスケツ
ヒメネス，デビッド ロペス
ヒメネス，デビッド ロペス
イバルグレンアイズピタルテ，マイタン
アイズピタルテ，マイタン イバルグレン
サルバドール，ホセ ハビエル ソト
サルバドール，ホセ ハビエル ソト
アスティズ，ミゲル ユース
アスティズ，ミゲル ユース
Original Assignee
ウニベルシダッド・デ・レス・イレス・バレアルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシダッド・デ・レス・イレス・バレアルス filed Critical ウニベルシダッド・デ・レス・イレス・バレアルス
Publication of JP2014530806A publication Critical patent/JP2014530806A/ja
Publication of JP2014530806A5 publication Critical patent/JP2014530806A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C07C51/493—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014533953A 2011-10-07 2012-10-08 脂肪酸の２−ヒドロキシド誘導体のエナンチオマー Pending JP2014530806A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES201131622A ES2401629B1 (es) 2011-10-07 2011-10-07 Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
ESP201131622 2011-10-07
US201261610762P 2012-03-14 2012-03-14
US61/610,762 2012-03-14

Publications (2)

Publication Number Publication Date
JP2014530806A true JP2014530806A (ja) 2014-11-20
JP2014530806A5 JP2014530806A5 (enExample) 2015-06-25

Family

ID=48043212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533953A Pending JP2014530806A (ja) 2011-10-07 2012-10-08 脂肪酸の２−ヒドロキシド誘導体のエナンチオマー

Country Status (12)

Country Link
US (1) US9359281B2 (enExample)
EP (2) EP3287437B1 (enExample)
JP (1) JP2014530806A (enExample)
CN (1) CN104321300A (enExample)
DK (1) DK2774910T3 (enExample)
ES (3) ES2401629B1 (enExample)
HU (1) HUE035430T2 (enExample)
IN (1) IN2014CN03111A (enExample)
PL (1) PL2774910T3 (enExample)
PT (1) PT2774910T (enExample)
RU (2) RU2687967C2 (enExample)
WO (1) WO2013050644A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520385A (ja) * 2017-05-16 2020-07-09 アビリティ ファーマシューティカルズ エス．エル． 癌治療のための薬剤の組み合わせ
JP2023518640A (ja) * 2020-01-29 2023-05-08 ウニバシタット デ レス イレス バレアース αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
AU2015334964B2 (en) * 2014-10-21 2019-06-20 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
KR20220140723A (ko) * 2020-02-10 2022-10-18 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합
WO2024063611A2 (ko) * 2022-09-23 2024-03-28 박진병 지방산 수용체를 강하게 활성화시키는 장쇄 지방산 또는 이의 유도체
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
AUPR547601A0 (en) * 2001-06-05 2001-06-28 Carcraft Qld Pty Ltd Tab with writing surface
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520385A (ja) * 2017-05-16 2020-07-09 アビリティ ファーマシューティカルズ エス．エル． 癌治療のための薬剤の組み合わせ
JP7208650B2 (ja) 2017-05-16 2023-01-19 アビリティ ファーマシューティカルズ エス．エル． 癌治療のための薬剤の組み合わせ
JP2023518640A (ja) * 2020-01-29 2023-05-08 ウニバシタット デ レス イレス バレアース αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用
JP7736313B2 (ja) 2020-01-29 2025-09-09 ウニバシタット デ レス イレス バレアース αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用

Also Published As

Publication number Publication date
EP2774910A1 (en) 2014-09-10
RU2017141446A (ru) 2019-02-13
IN2014CN03111A (enExample) 2015-07-03
RU2687967C2 (ru) 2019-05-17
RU2017141446A3 (enExample) 2019-02-13
CN104321300A (zh) 2015-01-28
EP3287437A1 (en) 2018-02-28
ES2401629A1 (es) 2013-04-23
RU2014118123A (ru) 2015-11-20
US9359281B2 (en) 2016-06-07
EP2774910A4 (en) 2015-02-25
ES2773784T3 (es) 2020-07-14
WO2013050644A1 (es) 2013-04-11
ES2401629B1 (es) 2014-03-04
ES2653675T3 (es) 2018-02-08
RU2637937C2 (ru) 2017-12-08
HUE035430T2 (en) 2018-05-02
DK2774910T3 (en) 2018-01-08
US20140288176A1 (en) 2014-09-25
EP3287437B1 (en) 2019-12-11
EP2774910B1 (en) 2017-09-27
PL2774910T3 (pl) 2018-03-30
PT2774910T (pt) 2018-01-03

Similar Documents

Publication Publication Date Title
RU2637937C2 (ru) Энантиомеры 2-гидроксипроизводных жирных кислот
JP2014530806A5 (enExample)
AU2019226257B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments
AU2021269396B2 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN107428652B (zh) 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
JP2019142887A (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
EP3567025B1 (en) Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
RU2441061C2 (ru) Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
HK40009140A (en) Use of derivatives of polyunsaturated fatty acids as medicaments
HK1232430B (zh) 多不饱和脂肪酸的衍生物作为药物的用途
HK1232207B (zh) 多不饱和脂肪酸的衍生物作为药物的用途
Kautzmann Elovanoids are a novel class of homeostatic lipid mediators that protect neural cell integrity upon injury
KR20210042385A (ko) 항-염증 화합물에 대한 구조화된 분자 벡터 및 이의 용도
HK1232430A1 (en) Use of derivates of polyunsaturated fatty acids as medicaments
HK1232430A (en) Use of derivates of polyunsaturated fatty acids as medicaments
Akbar et al. Role of omega-3 fatty acids in the brain and their signaling mechanisms

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150507